Measurement of permeability using a bench-top centrifuge

The commonly used British Standard constant head triaxial permeability test for testing of fine-grained soils is relatively time consuming. A reduction in the required time for soil permeability testing would provide potential cost savings to the construction industry, particularly in the construction quality assurance of landfill clay liners. The purpose of this paper is to evaluate an alternative approach of measuring permeability of fine-grained soils benefiting from accelerated time scaling for seepage flow when testing specimens in elevated gravity conditions provided by a centrifuge. As part of the investigation, an apparatus was designed and produced to measure water flow through soil samples under conditions of elevated gravitational acceleration using a small desktop laboratory centrifuge. A membrane was used to hydrostatically confine the test sample. A miniature data acquisition system was designed and incorporated in the apparatus to monitor and record changes in head and flow throughout the tests. Under enhanced gravity in the centrifuge, the flow through the sample was under ‘variable head' conditions as opposed to ‘constant head' conditions as in the classic constant head permeability tests conducted at 1 g . A mathematical model was developed for analysis of Darcy's coefficient of permeability under conditions of elevated gravitational acceleration and verified using the results obtained. The test data compare well with the results on analogous samples obtained using the classical British Standard constant head permeability tests.

Strategies for detection and quantification of cysteine cathepsins-evolution from bench to bedside

The cysteine cathepsins are a family of closely related thiol proteases, normally found in the endosomal and lysosomal compartments of cells. A growing body of evidence has clearly linked the dysregulated activity of these proteases with many diseases and pathological conditions, offering therapeutic, prognostic and diagnostic potential. However, these proteases are synthesised as inactive precursors and once activated, are controlled by factors such as pH and presence of endogenous inhibitors, meaning that overall protein and activity levels do not necessarily correlate. In order to fully appreciate the role and potential of these proteases, tools are required that can detect and quantify overall cathepsin activity. Two main strategies have evolved; synthetic substrates and protease-labelling with affinity-binding probes (or activity-based probes). This review examines recent innovations in these approaches as the field moves towards developing tools that could ultimately be used in patients for diagnostic or prognostic applications.

Selecting the best targeted agent in first-line treatment of unresectable liver metastases from colorectal cancer:does the bench have the answers?

For physicians facing patients with organ-limited metastases from colorectal cancer, tumor shrinkage and sterilization of micrometastatic disease is the main goal, giving the opportunity for secondary surgical resection. At the same time, for the majority of patients who will not achieve a sufficient tumor response, disease control remains the predominant objective. Since FOLFOX or FOLFIRI have similar efficacies, the challenge is to define which could be the most effective targeted agent (anti-EGFR or anti-VEGF) to reach these goals. Therefore, a priori molecular identification of patients that could benefit from anti-EGFR or anti-VEGF monoclonal antibodies (i.e. the currently approved targeted therapies for metastatic colorectal cancer) is of critical importance. In this setting, the KRAS mutation status was the first identified predictive marker of response to anti-EGFR therapy. Since it has been demonstrated that tumors with KRAS mutation do not respond to anti-EGFR therapy, KRAS status must be determined prior to treatment. Thus, for KRAS wild-type patients, the choices that remain are either anti-VEGF or anti-EGFR. In this review, we present the most updated data from translational research programs dealing with the identification of biomarkers for response to targeted therapies.